Microdilution in vitro antifungal susceptibility of Exophiala dermatitidis, a systemic opportunist

Medical Mycology

Volumn 49, Issue 8, 2011, Pages 819-824

  Badali, H ^a,b   De Hoog, G S ^b   Sudhadham, M ^c   Meis, J F ^d  

^a MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b CBS KNAW FUNGAL BIODIVERSITY CENTRE   (Netherlands)

^c SUAN SUNANDHA RAJABHAT UNIVERSITY   (Thailand)

^d CANISIUS WILHELMINA HOSPITAL   (Netherlands)

Author keywords

Antifungal susceptibility; Black yeasts; Exophiala dermatitidis; Isavuconazole

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; CASPOFUNGIN; FLUCONAZOLE; ISAVUCONAZOLE; ITRACONAZOLE; POSACONAZOLE; TRIAZOLE; VORICONAZOLE;

AMPLIFIED FRAGMENT LENGTH POLYMORPHISM; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BROTH DILUTION; DNA SEQUENCE; ENVIRONMENTAL FACTOR; EXOPHIALA; EXOPHIALA DERMATITIDIS; FUNGAL STRAIN; FUNGUS ISOLATION; GENOTYPE; IN VITRO STUDY; MICROBIAL DIVERSITY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN;

ANTIFUNGAL AGENTS; EXOPHIALA; GENOTYPE; HUMANS; MICROBIAL SENSITIVITY TESTS; PHAEOHYPHOMYCOSIS; PYRIMIDINES; TRIAZOLES;

CHAETOTHYRIALES; EXOPHIALA DERMATITIDIS; FUNGI;

EID: 80054686167     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.3109/13693786.2011.583285     Document Type: Article

References (24)

1. Haase G, Skopnik H, Groten T, et al. Long-term fungal cultures from sputum of patients with cystic f brosis. Mycoses 1991; 34: 373-376.
2. Badali H, Gueidan C, Najafzadeh MJ, et al. Biodiversity of the genus Cladophialophora. Stud Mycol 2008; 61: 175-191.
3. Badali H, Najafzadeh MJ, Van Esbroeck M, et al. The clinical spectrum of Exophiala jeanselmei, with a case report and in vitro antifungal susceptibility of the species. Med Mycol 2010; 48: 318-327.
4. Chang CL, Kim DS, Park DJ, et al. Acute cerebral phaeohyphomy-cosis due to Wangiella dermatitidis accompanied by cerebrospinal f uid eosinophilia. J Clin Microbiol 2000; 38: 1965-1966. (Pubitemid 30253945)
5. De Hoog GS, Matos T, Sudhadham M, et al. Intestinal prevalence of the neurotropic black yeast Exophiala dermatitidis in healthy and impaired individuals. Mycoses 2005; 48: 142-145. (Pubitemid 40395485)
6. Nweze EI, Ezute S. Isolation and antifungal susceptibility of Exophiala dermatitidis isolates from human stool samples in Nigeria. Myco-pathologia 2010; 169: 201-206.
7. Sudhadham M, de Hoog GS, Menken SBJ, et al. Rapid screening for genotypes as possible markers of virulence in the neurotropic black yeast Exophiala dermatitidis using PCR-RFLP. J Microbiol Methods 2009; 80: 138-142.
8. Matos T, de Hoog GS, de Boer AG, et al. High prevalence of the neutrope Exophiala dermatitidis and related oligotrophic black yeasts in sauna facilities. Mycoses 2002; 45: 373-377. (Pubitemid 35357008)
9. Sudhadham M, Prakitsin S, Sivichai S, et al. The neurotropic black yeast Exophiala dermatitidis has a possible origin in the tropical rain forest. Stud Mycol 2008; 61: 145-155.
10. Vitale RG, Afeltra J, de Hoog GS, et al. In vitro activity of amphotericin B and itraconazole in combination with f ucytosine, sufadiazine and quinolones against Exophiala spinifera. J Antimicrob Chemother 2003; 51: 1297-1300. (Pubitemid 36622088)
11. Fothergill AW, Rinaldi MG, Sutton DA. Antifungal susceptibility testing of Exophiala spp.: a head-to-head comparison of amphotericin B, itraconazole, posaconazole and voriconazole. Med Mycol 2009; 47: 41-43.
12. Uijthof JMJ, de Hoog GS, de Cock AWAM, et al. PCR-based evaluation of pathology of strains of the black yeast Exophiala (Wangiella) dermatitidis. Mycoses 1994; 37: 235-242.
13. Clinical and Laboratory Standards Institute (CLSI). Reference Method for Broth Dlution Antifungal Susceptibility Testing of Filamentous Fungi. Approved Standard M38-A2, 2nd edn. Wayne, PA: Clinical and Laboratory Standards Institute, 2008.
14. Daniel WW. Biostatistics: A Foundation for Analysis in the Health Sciences, 5th edn. New York: John Wiley, 1987:528-558.
15. Badali H, de Hoog GS, Curfs-Breuker I, et al. Use of amplif ed fragment length polymorphism to identify 42 clinical Cladophialophora spp., related to cerebral phaeohyphomycosis with in vitro antifungal susceptibility. J Clin Microbiol 2010; 48: 2350-2356.
16. Odabasi Z, Paetznick VL, Rodriguez JR, et al. In vitro activity of an-idulafungin against selected clinically important mold isolates. Anti-microb Agents Chemother 2004; 48: 1912-1915. (Pubitemid 38544413)
17. Silveira F, Nucci M. Emergence of black moulds in fungal disease: epidemiology and therapy. Curr Opinion Infect Dis 2001; 14: 679-684. (Pubitemid 33141187)
18. Meletiadis J, Meis JF, de Hoog GS, Verweij PE. In vitro susceptibilities of 11 clinical isolates of Exophiala species to six antifungal drugs. Mycoses 2000; 43: 309-312.
19. Badali H, de Hoog GS, Curfs-Breuker I, Meis JF. In vitro activities of antifungal drugs against Rhinocladiella mackenziei, an agent of fatal brain infection. J Antimicrob Chemother 2009; 65: 175-177.
20. Revankar SG, Sutton DA. Melanized fungi in human disease. Clin Microbiol Rev 2010; 23: 884-928.
21. Li DM, Li RY, de Hoog GS, et al. Fatal Exophiala infections in China, with a report of seven cases. Mycoses 2010, doi:10.1111/j.1439-0507. 2010.01859
22. Li DM, de Hoog GS. Cerebral phaeohyphomycosis-a cure at what lengths? Lancet Infect Dis 2009; 9: 376-383.
23. Schwartz S, Thiel E. Cerebral aspergillosis: tissue penetration is the key. Med Mycol 2009; 47(Suppl. 1):S387-393.
24. Rüping MJ, Albermann N, Ebinger F, et al. Posaconazole concentrations in the central nervous system. J Antimicrob Chemother 2008; 62: 1468-1470.